[1]邓垒,张文珏,周宗玫,等.327例广泛期小细胞肺癌综合治疗的疗效分析[J].国际放射医学核医学杂志,2018,(1):1-8.[doi:10.3760/cma.j.issn.1673-4114.2018.01.001]
　Deng Lei,Zhang Wenjue,Zhou Zongmei,et al.Clinical outcomes of 327 patients with extensive-stage small cell lung cancer treated with chemotherapy combined with or without thoracic radiation therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2018,(1):1-8.[doi:10.3760/cma.j.issn.1673-4114.2018.01.001]
点击复制

327例广泛期小细胞肺癌综合治疗的疗效分析(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
期数:
2018年第1期
页码:
1-8
栏目:
临床研究
出版日期:
2018-03-20

文章信息/Info

Title:
Clinical outcomes of 327 patients with extensive-stage small cell lung cancer treated with chemotherapy combined with or without thoracic radiation therapy
作者:
邓垒1;  张文珏2;  周宗玫1;  李景涛3;  肖泽芬1;  陈东福1;  冯勤付1;  梁军1;  李晔雄1;  王绿化1
1. 100021, 国家癌症中心/中国医学科学院北京协和医学院肿瘤医院放疗科;
2. 518000, 中国医学科学院肿瘤医院深圳医院放疗科;
3. 100122, 北京市朝阳区三环肿瘤医院放疗科
Author(s):
Deng Lei1;  Zhang Wenjue2;  Zhou Zongmei1;  Li Jingtao3;  Xiao Zefen1;  Chen Dongfu1;  Feng Qinfu1;  Liang Jun1;  Li Yexiong1;  Wang Lyuhua1
1. Department of Radiation Oncology, National Cancer Center, Cancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100021, China;
2. Department of Radiation Oncology, Cancer Hospital, Chinese Academy of Medical Sciences, Shenzhen Center, Shenzhen 518000, China;
3. Department of Radiation Oncology, Beijing Chaoyang District Sanhuan Cancer Hospital, Beijing 100122, China
关键词:
肺肿瘤; 癌; 小细胞; 放射疗法; 化学疗法; 疗效评价
Keywords:
Lung neoplasms; Carcinoma; small cell; Radiotherapy; Chemotherapy; Currative effect
DOI:
10.3760/cma.j.issn.1673-4114.2018.01.001
摘要:
目的 比较广泛期小细胞肺癌（ES-SCLC）化疗后加或不加胸部放疗的疗效，为ES-SCLC患者的综合治疗提供依据。方法 回顾性分析2007年至2012年接受化疗±胸部放疗的327例初治ES-SCLC患者资料。其中，130例（39.8%）患者进行了胸部放疗（化放疗组），197例（60.2%）接受单纯化疗（单纯化疗组）。化疗方案以EP（依托泊苷+顺铂）、CE（卡铂+依托泊苷）方案为主，胸部放疗采用调强放射治疗，放疗剂量为32~67 Gy。采用Kaplan-Meier法计算生存率，Log Rank法进行单因素预后分析，Cox回归模型进行多因素预后分析。结果 全组随访率为95.1%。化疗后达完全缓解（CR）、部分缓解（PR）、稳定（SD）者分别占2.5%、76.1%和21.4%。全组中位生存时间为13.7个月，中位无进展生存时间（PFS）为9.3个月。化放疗组的生存时间和PFS均显著提高，中位生存时间为20.0个月，中位PFS为10.8个月，而单纯化疗组分别为11.4个月和7.7个月。化放疗组的2年、3年、5年总生存率（OS）分别为42.5%、27.8%、18.8%，而单纯化疗组分别为11.6%、6.6%、3.5%（χ2=50.730，P<0.001）。亚组分析结果显示，按初诊脑转移状态和化疗疗效（CR+PR、SD）分层，胸部放疗均能显著提高OS，但不能延长初诊有脑转移的患者的PFS。胸部放疗能显著降低化放疗组的局部区域复发率至19.2%，而单纯化疗组为75.6%（χ2=100.080，P<0.001）。结论 对于化疗后无进展的ES-SCLC，胸部放疗可提高局部控制率，延长患者的总生存时间和PFS。
Abstract:
Objective To evaluate the influence of thoracic radiation therapy (TRT) on the survival of patients with extensive-stage small cell lung cancer (ES-SCLC) after chemotherapy. Methods A retrospective review was conducted on patients with ES-SCLC who received chemotherapy±TRT from January 2007 to December 2012. Most patients received initial chemotherapy with carboplatin plus etoposide or chemotherapy with cisplatin plus etoposide. A total of 130 cases of patients (39.8%) underwent TRT. TRT was performed through intensive modified radiotherapy. The median thoracic radiation dose was 56 Gy(32-67 Gy), with 1.8-2.3 Gy per fractions. The Kaplan-Meier, Log Rank test, and Cox regression were used for survival analysis and identification of prognostic factors. Statistically significant difference was set at P<0.05. Results Overall, 327 consecutive patients were enrolled. The follow-up rate was 95.1%. Patients reaching complete response(CR), partial response(PR), and stable disease(SD) after chemotherapy accounted for 2.4%, 76.1%, and 21.4%, respectively. The median follow-up time for survival patients was 69 months. The median overall survival (OS) of the whole group was 13.7 months, and the median progression-free survival(PFS) was 9.3 months. These results showed that TRT significantly improved the OS and PFS of patients. The median OS was 20.0 and 11.4 months in the TRT and non-TRT groups, respectively. Correspondingly, their median PFS was 10.8 and 7.7 months, respectively. The two-, three-, and five-year OS were 42.5%, 27.8%, and 18.8% in the TRT group and 11.6%, 6.6%, and 3.5% in the non-TRT group, respectively(χ2=50.730, P<0.001). Stratified analysis indicated that TRT can increase the OS in all the subgroups when the participants were divided according to different brain metastasis statuses and responses after chemotherapy(CR+PR, SD). However, TRT cannot improve the PFS of patients with brain metastasis. TRT can significantly decrease the locoregional recurrence rate to 19.2% and that of the non-TRT group was approximately 75.6%(χ2=100.080, P<0.001). Conclusion TRT can significantly improve the OS and PFS and decrease the locoregional recurrence rate in all patients with ES-SCLC with different brain metastasis statuses and responses after chemotherapy.

参考文献/References:

[1] Govindan R, Page N, Morgensztern D, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years:analysis of the surveillance, epidemiologic, and end results database[J]. J Clin Oncol, 2006, 24(28):4539-4544. DOI:10.1200/JCO.2005.04.4859.
[2] van Meerbeeck JP, Fennell DA, De Ruysscher DK. Small-cell lung cancer[J]. Lancet, 2011, 378(9804):1741-1755. DOI:10.1016/S0140-6736(11)60165-7.
[3] Vallières E, Shepherd FA, Crowley J, et al. The IASLC Lung Cancer Staging Project:proposals regarding the relevance of TNM in the pathologic staging of small cell lung cancer in the forthcoming (seventh) edition of the TNM classification for lung cancer[J]. J Thoracic Oncol, 2009, 4(9):1049-1059. DOI:10.1097/JTO.0b013 e3181b27799.
[4] Karve SJ, Price GL, Davis KL, et al. Comparison of demographics, treatment patterns, health care utilization, and costs among elderly patients with extensive-stage small cell and metastatic non-small cell lung cancers[J/OL]. BMC Health Serv Res, 2014, 14:555[2017-12-04]. https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/25392276. DOI:10.1186/s12913-014-0555-8.
[5] Fiegl M, Pircher A, Waldthaler C, et al. Small steps of improvement in small-cell lung cancer(SCLC) within two decades:a comprehensive analysis of 484 patients[J]. Lung Cancer, 2014, 84(2):168-174. DOI:10.1016/j.lungcan.2014.02.005.
[6] Kalemkerian GP. Running in place:the 20th anniversary of the NCCN small cell lung cancer guidelines panel[J]. JNatl Compr Canc Netw, 2015, 13(6):704-706. DOI:10.6004/jnccn.2015.0084.
[7] Eckert F, Müller AC. SCLC extensive disease-treatment guidance by extent or/and biology of response?[J/OL]. Radiat Oncol, 2008, 3:33[2017-12-04]. https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/18831728. DOI:10.1186/1748-717X-3-33.
[8] Socinski MA, Bogart JA. Limited-stage small-cell lung cancer:the current status of combined-modality therapy[J]. J Clin Oncol, 2007, 25(26):4137-4145. DOI:10.1200/JCO.2007.11.5303.
[9] Jeremic B, Shibamoto Y, Nikolic N, et al. Role of radiation therapy in the combined-modality treatment of patients with extensive disease small-cell lung cancer:A randomized study[J]. J Clin Oncol, 1999, 17(7):2092-2099. DOI:10.1200/JCO.1999.17.7.2092.
[10] Giuliani ME, Atallah S, Sun A, et al. Clinical outcomes of extensive stage small cell lung carcinoma patients treated with consolidative thoracic radiotherapy[J]. Clin Lung Cancer, 2011, 12(6):375-379. DOI:10.1016/j.cllc.2011.03.028.
[11] Zhu H, Zhou Z, Wang Y, et al. Thoracic radiation therapy improves the overall survival of patients with extensive-stage small cell lung cancer with distant metastasis[J]. Cancer, 2011, 117(23):5423-5431. DOI:10.1002/cncr.26206.
[12] Gore EM, Hu C, Sun AY, et al. Randomized phase Ⅱ study comparing prophylactic cranial irradiation alone to prophylactic cranial irradiation and consolidative extracranial irradiation for extensive-disease small cell lung cancer (ED SCLC):NRG oncology RTOG 0937[J]. J Thorac Oncol, 2017, 12(10):1561-1570. DOI:10.1016/j.jtho.2017.06.015.
[13] Slotman BJ, van Tinteren H, Praag JO, et al. Use of thoracic radiotherapy for extensive stage small-cell lung cancer:a phase 3 randomised controlled trial[J]. Lancet, 2015, 385(9962):36-42.DOI:10.1016/S0140-6736(14)61085-0.
[14] Bremnes RM, Sundstrom S, Aaseb?U, et al. The value of prognostic factors in small cell lung cancer:results from a randomised multicenter study with minimum 5 year follow-up[J]. Lung Cancer, 2003, 39(3):303-313. DOI:10.1016/S0169-5002(02)00508-1.
[15] 张文珏, 周宗玫, 陈东福, 等. 广泛期SCLC化疗后IMRT的疗效分析[J]. 中华放射肿瘤学杂志, 2016, 25(1):14-17. DOI:10.3760/cma.j.issn.1004-4221.2016.01.004. Zhang WJ, Zhou ZM, Chen DF, et al. Clinical outcomes of extensive stage small cell lung cancer patients treated with intensive modified radiotherapy[J]. Chin J Radiat Oncol, 2016, 25(1):14-17.
[16] Yee D, Butts C, Reiman A, et al. Clinical trial of post-chemotherapy consolidation thoracic radiotherapy for extensive-stage small cell lung cancer[J]. Radiother Oncol, 2012, 102(2):234-238. DOI:10.1016/j.radonc.2011.08.042.

相似文献/References:

[1]麦卫平,张永林.能谱CT成像在肺癌诊断中的应用研究进展[J].国际放射医学核医学杂志,2016,40(1):77.[doi:10.3760/cma.j.issn.1673-4114.2016.01.015]
　Mai Weiping,Zhang Yonglin.Research progress of spectral imaging in the diagnosis of lung cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):77.[doi:10.3760/cma.j.issn.1673-4114.2016.01.015]
[2]李景涛,邓垒,张文珏,等.广泛期小细胞肺癌胸部IMRT后发生放射性肺炎的危险因素分析[J].国际放射医学核医学杂志,2016,40(2):100.[doi:10.3760/cma.j.issn.1673-4114.2016.02.003]
　Li Jingtao,Deng Lei,Zhang Wenjue,et al.Risk factor analysis for predicting radiation pneumonitis in extensive stage small cell lung cancer patients receiving IMRT thoracic radiotherapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):100.[doi:10.3760/cma.j.issn.1673-4114.2016.02.003]
[3]霍小东,王慧星,阎卫亮,等.血管内皮抑制素对125I近距离照射裸鼠肺癌移植瘤的增敏效应研究[J].国际放射医学核医学杂志,2016,40(5):357.[doi:10.3760/cma.j.issn.1673-4114.2016.05.006]
　Huo Xiaodong,Wang Huixing,Yan Weiliang,et al.Sensitization effect of endostatin for 125I brachytherapy on transplanted tumor in nude mice[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):357.[doi:10.3760/cma.j.issn.1673-4114.2016.05.006]
[4]张毓艺,姚稚明.18F-FDG PET/CT对非小细胞肺癌淋巴结分期诊断价值的研究进展[J].国际放射医学核医学杂志,2016,40(6):447.[doi:10.3760/cma.j.issn.1673-4114.2016.06.009]
　Zhang Yuyi,Yao Zhiming.The progress of 18F-FDG PET/CT in the diagnosis of N-staging of non-small cell lung cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):447.[doi:10.3760/cma.j.issn.1673-4114.2016.06.009]
[5]张艳兰,孙琦婷,武萍,等.呼吸门控PET/CT对于肺癌放疗靶区勾画的指导[J].国际放射医学核医学杂志,2015,39(2):105.[doi:10.3760/cma.j.issn.1673-4114.2015.02.001]
　Zhang Yanlan,Sun Qiting,Wu Ping,et al.Guiding the target delineation in radiation therapy of lung cancer by respiratory gated PET/CT[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(1):105.[doi:10.3760/cma.j.issn.1673-4114.2015.02.001]
[6]万绪明,许祖闪,侯红军.磁共振表观弥散系数变化率对肝细胞肝癌患者单次TACE术后疗效评价的应用价值[J].国际放射医学核医学杂志,2015,39(2):129.[doi:10.3760/cma.j.issn.1673-4114.2015.02.006]
　Wan Xuming,Xu Zushan,Hou Hongjun.Applieation value of the change ratio of apparent diffusion coefficient in the therapeutic evaluation of hepatocellular carcinoma treated by single transcatheter arterial chemoembolization[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(1):129.[doi:10.3760/cma.j.issn.1673-4114.2015.02.006]
[7]王振光,王洋洋.PET/CT显像在肝细胞肝癌诊断中的研究进展[J].国际放射医学核医学杂志,2015,39(2):175.[doi:10.3760/cma.j.issn.1673-4114.2015.02.016]
　Wang Zhenguang,Wang Yangyang.The development of PET/CT imaging in the diagnosis of hepatocellular carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(1):175.[doi:10.3760/cma.j.issn.1673-4114.2015.02.016]
[8]张高潮,马丽,寇莹,等.99Tcm-tetrofosmin SPECT诊断肺部肿瘤的临床价值[J].国际放射医学核医学杂志,2015,39(4):303.[doi:10.3760/cma.j.issn.1673-4114.2015.04.007]
　Zhang Gaochao,Ma Li,Kou Ying,et al.Clinical value of 99Tcm-tetrofosmin SPECT in the diagnosis of lung neoplasms[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(1):303.[doi:10.3760/cma.j.issn.1673-4114.2015.04.007]
[9]付畅,史大鹏,徐俊玲,等.不同组织学类型肺癌患者大脑静息葡萄糖代谢改变研究[J].国际放射医学核医学杂志,2014,38(2):75.[doi:10.3760/cma.j.issn.1673-4114.2014.02.002]
　Fu Chang,Shi Dapeng,Xu Junling,et al.The preliminary study of brain glucose metabolism changes in patients with lung cancer of different histological types[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(1):75.[doi:10.3760/cma.j.issn.1673-4114.2014.02.002]
[10]张俊涛.晚期肺癌125I粒子植入治疗近期疗效观察[J].国际放射医学核医学杂志,2014,38(2):94.[doi:10.3760/cma.j.issn.1673-4114.2014.02.006]
　Zhang Juntao.Short-term efficacy of 125I seeds implantation in the treatment of advanced lung cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(1):94.[doi:10.3760/cma.j.issn.1673-4114.2014.02.006]
[11]董佳丽,罗丹,李源,等.降低B7-H3蛋白对受照肺癌细胞A549细胞周期和凋亡的影响[J].国际放射医学核医学杂志,2017,41(3):193.[doi:10.3760/cma.j.issn.1673-4114.2017.03.007]
　Dong Jiali,Luo Dan,Li Yuan,et al.Study on the effects of B7-H3 down-regulation on cell cycle and apoptosis of lung cancer A549 cells[J].International Journal of Radiation Medicine and Nuclear Medicine,2017,41(1):193.[doi:10.3760/cma.j.issn.1673-4114.2017.03.007]

备注/Memo

备注/Memo:
收稿日期:2017-12-04。
基金项目:国家重大研发计划（2016YFC0904600）
通讯作者:周宗玫,Email:zhouzongmei2013@163.com
更新日期/Last Update: 2018-03-20